Dr. Huober on Selection Criteria for Adjuvant Systemic Therapy for Breast Cancer

Jens Huober, MD
Published: Monday, Apr 03, 2017



Jens Huober, MD, professor of gynecologic oncology, Ulm University Hospital, discusses selection criteria for adjuvant systemic therapy for patients with breast cancer

Not every patient should receive extended adjuvant endocrine treatment because it can be an overtreatment for many patients, explains Huober.

The best selection criteria currently available is the initial tumor size, particularly if the patient has node-positive or node-negative disease. Other biological adverse prognostic features, such as high-proliferation index or T3 tumors, are also potential selection criteria, states Huober.
 


Jens Huober, MD, professor of gynecologic oncology, Ulm University Hospital, discusses selection criteria for adjuvant systemic therapy for patients with breast cancer

Not every patient should receive extended adjuvant endocrine treatment because it can be an overtreatment for many patients, explains Huober.

The best selection criteria currently available is the initial tumor size, particularly if the patient has node-positive or node-negative disease. Other biological adverse prognostic features, such as high-proliferation index or T3 tumors, are also potential selection criteria, states Huober.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Cancer Summaries and Commentaries™: Update from Chicago: Advances in the Treatment of Breast CancerJul 31, 20181.0
Community Practice Connections™: Medical Crossfire®: Translating Lessons Learned with PARP Inhibition to the Treatment of Breast Cancer—Expert Exchanges on Novel Strategies to Personalize CareAug 29, 20181.5
Publication Bottom Border
Border Publication
x